Barclays
APGE

Barclays’s Apogee Therapeutics APGE Stock Holding History

Barclays’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.66M Sell
20,031
-30,365
-60% -$2.74M ﹤0.01% 2200
2026
Q1 		$4.24M Sell
50,396
-82,797
-62% -$6.01M ﹤0.01% 1920
2025
Q4 		$10.1M Sell
133,193
-509,123
-79% -$32.1M ﹤0.01% 1668
2025
Q3 		$25.5M Buy
642,316
+33,494
+6% +$1.28M 0.01% 1089
2025
Q2 		$26.4M Buy
608,822
+110,197
+22% +$4.19M 0.01% 977
2025
Q1 		$18.6M Buy
498,625
+21,865
+5% +$845K 0.01% 1073
2024
Q4 		$21.6M Buy
476,760
+111,714
+31% +$5.7M 0.01% 1078
2024
Q3 		$21.4M Buy
365,046
+287,243
+369% +$13.8M 0.01% 1033
2024
Q2 		$3.06M Buy
77,803
+41,157
+112% +$2M ﹤0.01% 1845
2024
Q1 		$2.44M Buy
36,646
+2,590
+8% +$113K ﹤0.01% 2410
2023
Q4 		$952K Buy
+34,056
New +$683K ﹤0.01% 3466

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Barclays's APGE Position: Q2 2026 in Review

Barclays reduced its Apogee Therapeutics (APGE) stake by 60% in Q2 2026, selling an estimated $2.74M and leaving 20,031 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2200.

Barclays first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. The position peaked at $26.4M in Q2 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Barclays held 20,031 shares of Apogee Therapeutics worth $2.66M as of Q2 2026.
  • Barclays sold 30,365 Apogee Therapeutics shares in Q2 2026, an estimated $2.74M.
  • Apogee Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2200 holding.
  • Barclays first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Barclays's Apogee Therapeutics position peaked at $26.4M in Q2 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.